ING sets EUR 304 target for UCB stock as Galvokimig advances

Published on 10/05/2026 at 09:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galvokimig enrollment moved results to 2027 from 2028. UCB stock costs EUR 204.50 on October 5, 2026 after EUR 205.00, minus 0.24 percent.

Makroaufnahme eines dreidimensionalen Molekülmodells mit farbigen Kugeln vor unscharfem Laborhintergrund — UCB S.A. (BE0003739530) veranschaulicht durch scharfe Makroaufnahme einer dreidimensionalen Molekülstruktur im Forschungslabor, Illustration mit AI erstellt.

UCB (ISIN BE0003739530) completed Galvokimig enrollment ahead of schedule, and ING set a EUR 304.00 target for UCB stock on September 23, 2026. According to MarketScreener, the Belgian drugmaker now expects results from the phase IIb study by the end of 2027, versus 2028 previously. The timing improves the pipeline story, while the target sits 48.66 percent above the Lang & Schwarz price of EUR 204.50.

Galvokimig moves ahead

The study is testing Galvokimig in moderate to severe atopic dermatitis and is moving from intravenous development toward subcutaneous dosing. ING described the program as an important medium-term driver for UCB's dermatology position and maintained a buy recommendation with the EUR 304.00 target, according to the September 23, 2026 report linked above.

UCB's investor materials show the commercial base behind that pipeline investment. BIMZELX sales reached EUR 1.52 billion in the first half of 2026, while CIMZIA sales stood at EUR 954.00 million and Briviact sales at EUR 327.00 million in the same period, according to UCB.

Products carry the growth

The investor page also lists peak sales guidance of more than EUR 7 billion for BIMZELX and more than 135,000 patients reached globally in the first half of 2026. Those figures put Galvokimig in a broader portfolio context: UCB is using established immunology revenue to fund additional clinical programs while older products face exclusivity pressure.

At the September 23, 2026 J.P. Morgan European Healthcare CEO Call Series, management cited a 43 percent placebo-adjusted EASI 90 response rate from the phase IIa Galvokimig study. Investing.com also reported that BIMZELX had treated about 150,000 patients since launch and reached 80 percent marketplace access. Management cautioned that the phase IIa result is not directly comparable with phase III data for competing treatments, keeping the phase IIb readout central to the investment case.

EUR 304.00 target versus EUR 204.50

UCB stock was trading at EUR 204.50 at Lang & Schwarz on October 5, 2026 at 9:03 a.m. CEST, down 0.24 percent versus the prior close of EUR 205.00 on October 2, 2026. The quoted market capitalization was EUR 38.9 billion on October 2, 2026, while the 52-week range was EUR 200.20 to EUR 289.50.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.